Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial
Introduction: Elotuzumab, a monoclonal antibody targeting SLAM family member 7 protein (SLAMF7) on multiple myeloma (MM) cells, has shown promise in relapsed/refractory MM when combined with immunomodulatory agents. However, its effectiveness in newly diagnosed patients did not show improved progres...
Saved in:
Published in | Blood Vol. 142; no. Supplement 1; p. 1991 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
02.11.2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction: Elotuzumab, a monoclonal antibody targeting SLAM family member 7 protein (SLAMF7) on multiple myeloma (MM) cells, has shown promise in relapsed/refractory MM when combined with immunomodulatory agents. However, its effectiveness in newly diagnosed patients did not show improved progression-free survival (PFS) nor overall survival. In a previous study we demonstrated that elotuzumab specifically depleted high SLAMF7 expressing regulatory CD8 + T cells by macrophage induced antibody dependent phagocytosis. This study aimed to identify immunological predictive factors for elotuzumab efficacy, enabling improved risk stratification and personalized treatment decisions based on the detection and quantification of SLAMF7-positive T cell subsets.
Patients and Methods: This pre-planned accompanying immunological research analyzed samples from the German-Speaking Myeloma Multicenter Group (GMMG) HD6 clinical trial (NCT02495922). The trial investigated elotuzumab in combination with lenalidomide/bortezomib/dexamethasone induction and consolidation, followed by lenalidomide maintenance in transplant-eligible newly diagnosed MM patients and found no progression-free or overall survival advantage with the addition of elotuzumab in any treatment sequence. Peripheral blood samples were collected at three time points: trial inclusion (T1), after induction therapy (T2), and during consolidation or maintenance therapy (T3). Flow cytometry was used to assess T cell subpopulations.
Results: Elotuzumab during induction therapy significantly reduced the percentage of regulatory SLAMF7 high expressing CD8 + CD28 - ( p < 0.001) and effector CD8 + T cells ( p < 0.001) in MM patients after induction therapy and during maintenance therapy. A T2 landmark multivariate analysis (after induction therapy) revealed that a higher percentage of effector CD8 + T cells at T1 showed a borderline advantageous effect on the progression-free survival (PFS) ( HR = 0.98 [CI 95% 0.97; 1.00], p = 0.010) regardless of the study arm. Further, in a multivariate analysis a high regulatory CD8 + T cell level at T2 was associated with an adverse PFS in patients receiving elotuzumab in addition to lenalidomide during consolidation and maintenance (PFS from T2 for high vs. low regulatory CD8 + T cell levels at T2, HR = 3.64 [CI 95% 1.58; 8.36], p = 0.002 for patients that received elotuzumab during consolidation and maintenance only; regulatory CD8 + T cells at T2 [high versus low] HR = 5.93 [CI 95% 2.30; 15.26], p < 0.001 for patients that received elotuzumab during induction, consolidation and maintenance).
Conclusion: The efficacy of elotuzumab in MM patients may be influenced by the frequency of regulatory CD8 + T cells after induction therapy. As high levels of regulatory CD8 + T cells showed adverse progression-free survival in MM patients, the assessment of the level of regulatory CD8 + SLAMF7 + T cells could be a prerequisite for MM patients' response to elotuzumab. This study highlights the importance of T cell level-driven immunological treatment approaches when utilizing elotuzumab. |
---|---|
AbstractList | Introduction: Elotuzumab, a monoclonal antibody targeting SLAM family member 7 protein (SLAMF7) on multiple myeloma (MM) cells, has shown promise in relapsed/refractory MM when combined with immunomodulatory agents. However, its effectiveness in newly diagnosed patients did not show improved progression-free survival (PFS) nor overall survival. In a previous study we demonstrated that elotuzumab specifically depleted high SLAMF7 expressing regulatory CD8 + T cells by macrophage induced antibody dependent phagocytosis. This study aimed to identify immunological predictive factors for elotuzumab efficacy, enabling improved risk stratification and personalized treatment decisions based on the detection and quantification of SLAMF7-positive T cell subsets.
Patients and Methods: This pre-planned accompanying immunological research analyzed samples from the German-Speaking Myeloma Multicenter Group (GMMG) HD6 clinical trial (NCT02495922). The trial investigated elotuzumab in combination with lenalidomide/bortezomib/dexamethasone induction and consolidation, followed by lenalidomide maintenance in transplant-eligible newly diagnosed MM patients and found no progression-free or overall survival advantage with the addition of elotuzumab in any treatment sequence. Peripheral blood samples were collected at three time points: trial inclusion (T1), after induction therapy (T2), and during consolidation or maintenance therapy (T3). Flow cytometry was used to assess T cell subpopulations.
Results: Elotuzumab during induction therapy significantly reduced the percentage of regulatory SLAMF7 high expressing CD8 + CD28 - ( p < 0.001) and effector CD8 + T cells ( p < 0.001) in MM patients after induction therapy and during maintenance therapy. A T2 landmark multivariate analysis (after induction therapy) revealed that a higher percentage of effector CD8 + T cells at T1 showed a borderline advantageous effect on the progression-free survival (PFS) ( HR = 0.98 [CI 95% 0.97; 1.00], p = 0.010) regardless of the study arm. Further, in a multivariate analysis a high regulatory CD8 + T cell level at T2 was associated with an adverse PFS in patients receiving elotuzumab in addition to lenalidomide during consolidation and maintenance (PFS from T2 for high vs. low regulatory CD8 + T cell levels at T2, HR = 3.64 [CI 95% 1.58; 8.36], p = 0.002 for patients that received elotuzumab during consolidation and maintenance only; regulatory CD8 + T cells at T2 [high versus low] HR = 5.93 [CI 95% 2.30; 15.26], p < 0.001 for patients that received elotuzumab during induction, consolidation and maintenance).
Conclusion: The efficacy of elotuzumab in MM patients may be influenced by the frequency of regulatory CD8 + T cells after induction therapy. As high levels of regulatory CD8 + T cells showed adverse progression-free survival in MM patients, the assessment of the level of regulatory CD8 + SLAMF7 + T cells could be a prerequisite for MM patients' response to elotuzumab. This study highlights the importance of T cell level-driven immunological treatment approaches when utilizing elotuzumab. |
Author | Schlenzka, Jana Weisel, Katja Hose, Dirk Hundemer, Michael Munder, Markus Neubauer, Andreas Weinhold, Niels Huhn, Stefanie Goldschmidt, Hartmut Schroers, Roland Kriegsmann, Katharina Benner, Axel Ton, Gigi Nu Hoang Quy Kremers, Stephan Jauch, Anna Raab, Marc S. Salwender, Hans Mai, Elias K. Schieferdecker, Aneta Besemer, Britta Seidel-Glätzer, Andrea von Metzler, Ivana Müller-Tidow, Carsten Graeven, Ullrich Martens, Uwe Thomalla, Jörg Awwad, Mohamed H.S. Fenk, Roland Blau, Igor Wolfgang Kunz, Christian Hänel, Mathias Dürig, Jan Bertsch, Uta Hensel, Manfred Scheid, Christof Reimer, Peter Mahlberg, Rolf |
Author_xml | – sequence: 1 givenname: Gigi Nu Hoang Quy surname: Ton fullname: Ton, Gigi Nu Hoang Quy – sequence: 2 givenname: Katharina surname: Kriegsmann fullname: Kriegsmann, Katharina – sequence: 3 givenname: Mohamed H.S. surname: Awwad fullname: Awwad, Mohamed H.S. – sequence: 4 givenname: Axel surname: Benner fullname: Benner, Axel – sequence: 5 givenname: Uta surname: Bertsch fullname: Bertsch, Uta – sequence: 6 givenname: Britta surname: Besemer fullname: Besemer, Britta – sequence: 7 givenname: Mathias surname: Hänel fullname: Hänel, Mathias – sequence: 8 givenname: Roland surname: Fenk fullname: Fenk, Roland – sequence: 9 givenname: Jana surname: Schlenzka fullname: Schlenzka, Jana – sequence: 10 givenname: Markus surname: Munder fullname: Munder, Markus – sequence: 11 givenname: Jan surname: Dürig fullname: Dürig, Jan – sequence: 12 givenname: Igor Wolfgang surname: Blau fullname: Blau, Igor Wolfgang – sequence: 13 givenname: Stefanie surname: Huhn fullname: Huhn, Stefanie – sequence: 14 givenname: Dirk surname: Hose fullname: Hose, Dirk – sequence: 15 givenname: Anna surname: Jauch fullname: Jauch, Anna – sequence: 16 givenname: Andreas surname: Neubauer fullname: Neubauer, Andreas – sequence: 17 givenname: Niels surname: Weinhold fullname: Weinhold, Niels – sequence: 18 givenname: Christof surname: Scheid fullname: Scheid, Christof – sequence: 19 givenname: Roland surname: Schroers fullname: Schroers, Roland – sequence: 20 givenname: Ivana surname: von Metzler fullname: von Metzler, Ivana – sequence: 21 givenname: Aneta surname: Schieferdecker fullname: Schieferdecker, Aneta – sequence: 22 givenname: Jörg surname: Thomalla fullname: Thomalla, Jörg – sequence: 23 givenname: Peter surname: Reimer fullname: Reimer, Peter – sequence: 24 givenname: Rolf surname: Mahlberg fullname: Mahlberg, Rolf – sequence: 25 givenname: Ullrich surname: Graeven fullname: Graeven, Ullrich – sequence: 26 givenname: Stephan surname: Kremers fullname: Kremers, Stephan – sequence: 27 givenname: Uwe surname: Martens fullname: Martens, Uwe – sequence: 28 givenname: Christian surname: Kunz fullname: Kunz, Christian – sequence: 29 givenname: Manfred surname: Hensel fullname: Hensel, Manfred – sequence: 30 givenname: Andrea surname: Seidel-Glätzer fullname: Seidel-Glätzer, Andrea – sequence: 31 givenname: Katja surname: Weisel fullname: Weisel, Katja – sequence: 32 givenname: Hans surname: Salwender fullname: Salwender, Hans – sequence: 33 givenname: Carsten surname: Müller-Tidow fullname: Müller-Tidow, Carsten – sequence: 34 givenname: Marc S. surname: Raab fullname: Raab, Marc S. – sequence: 35 givenname: Hartmut surname: Goldschmidt fullname: Goldschmidt, Hartmut – sequence: 36 givenname: Elias K. surname: Mai fullname: Mai, Elias K. – sequence: 37 givenname: Michael surname: Hundemer fullname: Hundemer, Michael |
BookMark | eNot0EFPwjAcBfDGYCKgH8Bbv0D1327rNm8GEUhYJJH70nXtqOla0m4HvPnNFfD0Di95L_nN0MR5pxB6pPBEacGeG-t9SxiwhNCipLy8QVOasYIAMJigKQBwkpY5vUOzGL8AaJqwbIp-Nn0_Om99Z6Sw-HNsuuDHY8S7oFojB-M6vNT6r5Qn7DVeWj-M32MvGmwcrkY7mKNVuDop63uBd2Iwyg3xBW9cNN1hiFgH3-PhoPCqqlZk_cbxwhp3edsHI-w9utXCRvXwn3O0f1_uF2uy_VhtFq9bIousJC2VAGnDS500Uui8zZmWLRVlU7IENNcpp1wzoTORpDLNFaRZnnNe6IJqBZDMEb3OyuBjDErXx2B6EU41hfpMWF8I6zNhfSVMfgEnLGko |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1182/blood-2023-189169 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 1991 |
ExternalDocumentID | 10_1182_blood_2023_189169 |
GroupedDBID | --- -~X .55 0R~ 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 6J9 AAEDW AALRI AAXUO AAYXX ABOCM ACGFO ADBBV AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D WH7 WOQ WOW X7M YHG YKV |
ID | FETCH-LOGICAL-c859-d1c004b69f3bcaf7d72fcd1a9b9230f6f4616f2af5a34c47e04577668f81fe003 |
ISSN | 0006-4971 |
IngestDate | Thu Sep 12 17:25:52 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c859-d1c004b69f3bcaf7d72fcd1a9b9230f6f4616f2af5a34c47e04577668f81fe003 |
OpenAccessLink | https://doi.org/10.1182/blood-2023-189169 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_2023_189169 |
PublicationCentury | 2000 |
PublicationDate | 2023-11-02 |
PublicationDateYYYYMMDD | 2023-11-02 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-02 day: 02 |
PublicationDecade | 2020 |
PublicationTitle | Blood |
PublicationYear | 2023 |
SSID | ssj0014325 |
Score | 2.4746778 |
Snippet | Introduction: Elotuzumab, a monoclonal antibody targeting SLAM family member 7 protein (SLAMF7) on multiple myeloma (MM) cells, has shown promise in... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 1991 |
Title | Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial |
Volume | 142 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIh4XBF1WvOUD4kCVpUkcJ-FWytICykorirS3ynHiUqlNEG207N74bfwxZhw7SVmQWC5WmlaWk_k645n5xkPIc9eXMnCRPSXSwGGRcB3BsJkZS_0MOyBJHwuFk2M-_cw-nAanvd7PDmup2qaH8uKPdSX_I1W4B3LFKtkrSLaZFG7ANcgXRpAwjP8k4_dY3NFoL9ABukZjg7yKDEs9igV2ToYvpc6jH63KbXVRrUWKUY7EUgmT83xVrgWe1r_UtAp_hBwC9No3bfnJJEkmzvQtH4xtLeUMn3AnKbwynefrsLXWZ5PlYjk4rgbTUsBqTqomgg_aJV9s1qZHM5I6wGsvGiMxOjurwZeUXwRY7MH08NNhEzvIbcOw0XdD-TeBC8_XFXzejjLm2OCuhlZu9C8emD30hjsKmnkdJOpupzp0OnA7mhcpXB0rbj9ethARnjhbVwXUq4pghxy35tBSAH6zkg13UXtNkTfXU8xxink9xTVy3QvjACMAH0_aVBbzvbqNhnlak1qHKV5dWkVnc9TZ5czukjvGPaGjGmv3SC8v-mR_VIhtuT6nL6gmDOtMTJ_ceGOvbo1t28A-uZkYtsY--bGDT9rgk7b4pBaftFS0xSddFtTikxp8UovP19SikyI6KaCTWnRSi06q0XmfzN4dzcZTx7T8cGQUxE7mSvh7pzxWfiqFCrPQUzJzRZyCHzJUXDHucuUJFQifSRbm4JCEIeeRilyVg4E6IHtFWeQP8CwC0JFKRSznMctSV0g2hDH0RDhkXPCH5KV91fOv9cEu87-K9tFVfvyY3G7h_oTsbb9V-VPYuW7TZxoZvwCl_ZnM |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunological+Subgroups+Predicting+Efficacy+of+Elotuzumab+in+Multiple+Myeloma+Patients%3A+Insights+from+the+GMMG-HD6+Clinical+Trial&rft.jtitle=Blood&rft.au=Ton%2C+Gigi+Nu+Hoang+Quy&rft.au=Kriegsmann%2C+Katharina&rft.au=Awwad%2C+Mohamed+H.S.&rft.au=Benner%2C+Axel&rft.date=2023-11-02&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=142&rft.issue=Supplement+1&rft.spage=1991&rft.epage=1991&rft_id=info:doi/10.1182%2Fblood-2023-189169&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_2023_189169 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |